Program Overview

The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative, fully online educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. Participants will learn how to recognize, screen, treat and refer patients with substance use disorders through 40 CME hours of interactive, case-based learning. This program is designed for healthcare professionals who received little addiction education during their medical training including physicians, clinicians, and other healthcare providers in primary care, emergency/urgent care, treatment centers and general psychiatry settings.

Requirements and Format

Registration to the program includes the online version of all activities. Participants may elect to complete activities in a live, in-person format when available to fulfill program requirements. Additional fees may apply for live-in-person events. Participants will have the opportunity to submit CME certificates for any of the required activities they have previously completed and will NOT need to re-take the activity. 

Program Activities

The ASAM Fundamentals of Addiction Medicine 40-Hour CME Program is comprised of five activities. All activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.  

Click on the buttons below to be taken to each of the program activities. While it is recommended, you take the activities in the order below, participants may complete in any order they choose.

Activity 1: FOAM   Activity 2: TOUD   Activity 3: ECHO Series   Activity 4: Pain Management   Activity 5: ElectiveS

Activity Description

• Activity 1 - The ASAM Fundamentals of Addiction Medicine Online (8 CME)

• Activity 2 - The ASAM Treatment of Opioid Use Disorder Course (8 CME)

• Activity 3 - Fundamentals of Addiction Medicine ECHO (FAME) Video-Conferencing Series (8 CME)

• Activity 4 - Pain Management and Opioids (2.5 CME)

• Activity 5 - Elective Topics (13.5 CME)

If you experience any difficulties, please call the ASAM office at 301-656-3920 or email education@asam.org.

Note: This program is for providers who are seeking additional knowledge about addiction medicine. This is not a certification or designed to prepare providers for certification exams. Providers interested in becoming an ABMS certified Addiction Specialist should go to http://www.theabpm.org and/or learn about Addiction Fellowship programs at https://www.acaam.org/accreditedfellowships/.  

About the Program

Program Overview

The ASAM Fundamentals of Addiction Medicine 40-Hour Program is an innovative educational program empowering primary care and other providers to identify, treat, and/or refer patients at risk for or with addiction. Participants will learn how to recognize, screen, treat and refer patients with substance use disorders through 40 CME hours of interactive, case-based learning. This program is designed for healthcare professionals who received little addiction education during their medical training including physicians, clinicians, and other healthcare providers in primary care, emergency/urgent care, treatment centers and general psychiatry settings.

Program Competencies

View Full Competencies

Competencies and Curriculum Learning Objectives

The ASAM Fundamentals of Addiction Medicine 40-Hour Program seeks to help learners achieve nine identified competencies in the addiction medicine field.

The 40 hour CME curriculum is structured around nine competencies, of which each competency has several learning objectives. Activities in the curriculum will align with at least one of the learning objectives.

1. Interact with patients and professional colleagues so as to display professionalism in all activities, by demonstrating commitment to the health and well-being of individuals and society through ethical practice, profession-led regulation, and high personal standards of behavior.
2. Identify their feelings and attitudes that promote or prevent therapeutic responses to their patients with substance use disorders.
3. Understand the addictive disorders as developmental biopsychosocial disorders.
4. Take an evidence-based approach to detecting substance use disorders. 
5. Respond to positive substance use screening results with brief counseling strategies, appropriate to the patient’s readiness to change.
6. Use motivational interviewing with patients ambivalent about changing their substance use behavior.
7. Conduct a biopsychosocial and developmental ambulatory assessment of an adult with a suspected SUD to match the patient to an appropriate level of care.
8. List the indications, contraindications and duration of treatment of evidence based pharmacotherapy for alcohol, tobacco, and opioid use disorders and refer patient to specialty care where appropriate. 
9. Reflect on the role of behavioral interventions for patients and families including formal intensive ambulatory and inpatient treatment and informal programs such as mutual aid groups in the recovery process for patients in their practice/ communities. 

Financial Disclosures

Commercial Interest Definition

A commercial interest is any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests.

Disclosure of Commercial Support

The American Society of Addiction gratefully acknowledges the support of the following companies in the development of The ASAM Fundamentals of Addiction Medicine Program. Indivior provided an unrestricted educational grant to assist with the development, implementation and evaluation of this Fundamentals Program.

ASAM Fundamentals of Addiction Medicine Workshop Planning Committee

ASAM CME Committee

Accreditation

Accreditation Council for Continuing Medical Education (ACCME)

The American Society of Addiction Medicine has been awarded the highest level of Accreditation with Commendation by the Accreditation Council for Continuing Medical Education (ACCME) as a provider of continuing medical education (CME) for physicians. Accreditation in the ACCME System seeks to assure the medical community and the public that ASAM delivers education that is relevant to clinicians’ needs, evidence-based, evaluated for its effectiveness, and independent of commercial influence. 

The ACCME System employs a rigorous process for evaluating institutions' CME programs according to standards that reflect the values of the educator community and aim to accelerate learning, inspire change, and champion improvement in healthcare. Through participation in accredited CME, clinicians and teams drive improvement in their practice and optimize the care, health, and wellness of their patients.

Please see individual sessions for accreditation information for specific offerings.

Why Participate?

Participants are saying....

• “This is probably the best post-graduate training I've ever done…The webinar format was engaging and educational. I greatly appreciate the opportunity to have involved at that level.” – MD, Massachusetts

• “Appreciate your effort to organize the training. It was a great experience. I'd definitely recommend this to my primary care colleagues.” – MD, Maryland

• “…living in the Northeast, I’m afraid I get very provincial so it’s been really interesting to hear everybody…but it’s the across the country responses that have been so helpful.” – MD, Massachusetts

• “Living in Alaska, the resources for substance abuse treatment is probably not as diversified as in other areas…so this clinic has been valuable to me… providing the information and talking, collaborating with other professions in the field to help provide the best care of the patients.” – NP, Alaska

Extensive Development from Experts.... 

The ASAM Fundamentals 40-Hour Program was developed over multiple years, beginning in 2013. ASAM’s committee of experts created, evaluated, and revised the Fundamentals program continuously to ensure providers received the highest quality, most up-to-date  education.

Competency-Based Program Activities...

The ASAM Fundamentals of Addiction Medicine 40-Hour Program is comprised of five components. All components and activities align with the nine identified addiction medicine competencies for primary care providers. ASAM has also gathered a collection of resources and tools reviewed by experts related to various topics of addiction medicine and working with patients at risk for or with substance use disorders (SUD) to supplement participant’s learning.   

Positive Outcomes for Participants' Practice...

Some of the most commonly reported changes as a result of the ASAM Fundamentals 40-Hour Program were:

• Change in patient treatment plans
• Change in approach to patients with SUDs
• More frequent screening, e.g. screening all patients at least annually.
• More use of screening tools or use of different screening tools.
• More or better use of SBIRT
• More or better use of MI techniques
• Increased confidence in treating patients with addiction

Friday, June 28, 2019 | 8:30 am CT - 1:00 pm CT

Centene Corporation - Auditorium, First Floor
7700 Forsyth Boulevard
St. Louis, MO 63105

Online Portion Due: June 27, 2019

This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

In the content section you will find 2 different components for the live learning. For those attending live in-person, you can skip over the live webinar portion to complete the CME Evaluation and claim your CME Certificate.

For those attending Live-Via Webinar, you will have access to the "Live Webinar" component 30 minutes before the training. You will click on this link to access the webinar on the 29th. 

Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

 If you have any questions, please contact education@ASAM.org.

1. Locate the box on the right that says “View Course" and click “View Course"
   1. A new window will open with the course. Be sure your pop-up blocker is turned off.
2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
3. You will be required to pass all CME Quizzes with a grade of 70% or higher
4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center

Learning Objectives

Module 1

1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

Module 2

6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

Module 3

9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

Overall

12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

CME Information and Disclosure Listing

Date of Release: July 2015 

Approved Through: December 2019

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

ASAM CME Committee

ASAM Medical Education Council

1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
• Complete not less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD  
• If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

• 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
• Clinical Tools, Inc
• Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Qualify 

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain
• Complete no less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD
• If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

This webinar helps build knowledge of The ASAM Appropriate Use of Drug Testing in Clinical Addiction Medicine document, which guides provider decisions about drug testing, as no universal standard exists today. It will allow providers, patients and their families, healthcare administrators, and payers determine clearly what is appropriate practice and what is considered outside the realm of appropriate practice in regard to drug testing in clinical addiction medicine. This webinar is primarily intended for addiction specialists and all providers utilizing drug testing in the context of the identification, diagnosis, treatment, and monitoring of patients with, or at risk for, addiction. It will also be useful for physicians and other providers concerned about the possibility of addiction in their patient population.

Upon completion of this activity, participants should be able to:
-Recognize the importance of the guidance needed around drug testing today
-Identify the fundamental components of drug testing in a clinical setting
-Summarize the document's recommendations and discuss how they should be used in practice
-Address common clinical questions around drug testing in a clinical setting

ASAM is part of a collaboration that made this course possible.

Educational Objectives

After completing this activity, the participant should be better able to:

Part 1

• Describe the prevalence of substance use and prescription drug misuse among adolescents
• Explain why adolescents are at high risk of developing a substance use disorder and how clinicians can help prevent it
• Demonstrate strategies to build trust with adolescent patients and ensure confidentiality when addressing substance use and prescription drug misuse
• Summarize ways to identify substance use and prescription drug misuse in adolescent patients, including determining their level of risk

Part 2

• Discuss strategies to address substance use and prescription drug misuse in adolescent patients based on their level of use
• Summarize when and how to follow up with adolescent patients who use substances or misuse prescription drugs

Joint Accreditation Statement

In support of improving patient care, this activity has been pl

anned and implemented by the Postgraduate Institute for Medicine and National Institute for Drug Abuse.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been reviewed and is acceptable for up to 1.00 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/30/2017. Term of approval is for one year from this date.

This continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 AAP credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

American Dental Association CERP Recognition

This continuing education activity has been planned and implemented in accordance with the standards of the ADA Continuing Education Recognition Program (ADA CERP) through joint sponsorship efforts between Postgraduate Institute for Medicine and the National Institute for Drug Abuse.

Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.  ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry.

Postgraduate Institute for Medicine designates this activity for 1.0 continuing education credit.

Education Coalition

This activity was developed by an education Coalition of experts and medical professional organization representatives. The Coalition comprises the following organizations and experts:

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The Education Coalition members reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Marc Fishman, MD discloses the following: Consulting Fees: US World Meds; Contracted Research: Media Rez, US World Meds

Ownership Interest: Maryland Treatment Centers

The following Education Coalition members have nothing to disclose: Cynthia Kear, Jennifer Butchart, Penny Mills, Arlene Deverman, Stephanie Townsell, Marla Kushner, Anne Norman, Renee Jarrett, Daniel Pace, Marie-Michele Leger, Sara Evans, Vincent DiFabio, Jan Schultz, Dan Alford, Sharon Levy, Jeff Baxter, Marc Fishman, and Carol Havens

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following National Institute on Drug Abuse planners and managers, Elisabeth Davis; Carol Krause; Josie Anderson; Jack Stein, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

The following JBS International, Inc. planners and managers, Candace Baker; Susan Hayashi; Laura Nolan; Bethel Arya; and Veronica Junghahn, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months

For Physicians, Registered Nurses and Dentists, please follow the instructions below:

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. Go to CME University at: www.cmeuniversity.com and register or login
2. Once logged in, click on “Find Post-test/Evaluation by Course” at the top of the page
3. Type in 11118 (for Part1) or 12614 (for Part 2) in the box; hit enter
4. Click on the activity title
5. Complete the online posttest and evaluation and obtain your CME certificate to download and/or print for your files.

Upon completion of the online posttest and evaluation form, you will have immediate access to a certificate of attendance to print or save for your files. You can save your certificate by selecting the “Save” option on the print screen. 

For any questions relating to the physician, nursing or dentist accreditation, please contact PIM via:  inquiries@pimed.com

For Nurse Practitioners follow the instructions below:

• Visit the AANP’s Website (coming soon) to take the course for AANP credit.

For Physician Assistants follow the instructions below:

• Visit the AAPA’s Website to take the course for AAPA credit.

For Doctors of Osteopathic Medicine follow the instructions below:

      Visit the AOA’s Website (coming soon) to take the course for AOA credit.

Internet activity

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

The 60-minute webinar will provide insights into current addiction treatment gap and how physicians can close this gap by becoming board-certified in addiction medicine certified through the upcoming American Board of Preventive Medicine addiction medicine exam

This webinar is targeted toward clinicians, physicians, academicians and other addiction medicine professionals looking to learn more the addiction treatment gap and the new addiction medicine subspecialty under the American Board of Preventive Medicine (ABPM). 

The purpose of the webinar is to emphasize the need to close the current treatment gap and increase the addiction medicine workforce. There will be a key focus on the new addiction medicine subspecialty and the pathways for certification. There will be a live question and answer session during the webinar to address any concerns and foster conversation around this monumental development in the field. 

• Addiction medicine specialists
• Opioid treatment program providers
• DATA-waived provider
• Public health management services providers

Upon completion of this activity, participants will be able to:

•  Demonstrate the importance of the need for an expanded workforce.  
•  Describe the different hurdles patients faces when seeking treatment for addiction treatment.
•  Identify different demographics that are uniquely affected by the treatment gap.
•  Diagram the different learning methods physicians can take to educate themselves in addiction medicine.
•  Construct an outline of the different pathways physicians can take to become eligible to sit for the addiction medicine exam.
•  Identify certain criteria physicians have to uphold in order to become an addiction specialist. 

ACCME Accreditation Statement The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

 AMA Credit Designation Statement: The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ASAM 2017-2018 CME Committee Disclosure Information:

April 7, 2017 – April 2018

This free CME webinar series is designed to prepare physicians and their billing staff for the basics of modern healthcare payment models and methods of incorporating these models into addiction treatment practice. Presented by a healthcare reimbursement expert, viewers will learn the language used by health payers to improve understanding of billing and coding techniques. Some tips about determining patient coverage for services, handling prior authorization requests, and submitting claims to payers will be included.

The first in the series created to examine some of the basic and advanced issues that many may face when working with insurance companies and other health payers. The second webinar will be held on March 7th, and the third session will be a panel discussion held at the Annual Conference with ASAM members employed by health insurers.

This webinar is primarily intended for addiction medicine specialists; medical office billing staff; opioid treatment program providers; DATA-waived providers

At the conclusion of the webinar, participants should be able to:

• Recognize health care reimbursement models and common terms used by most health care payers
• Explain how health care payers make coverage decisions and discuss how that relates to their practice
• Explain recent or upcoming policy changes and identify implications or areas for provider involvement
• Assess the importance of utilization management requests, appeals, and compliance protections to make informed decisions in their practice
• Synthesize information to assist patients and staff with coverage questions and appeals
• Evaluate billing best practices to appropriately bill for tasks performed in basic or advanced situations
• Create a set of resources/list of best practices that can be used to support the participant's practice
• Analyze information about payers/reimbursement models to develop a plan for personal engagement with payer to positively impact their practice.

ACCME Accreditation Statement
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

 AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA
PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This free CME webinar series is designed to prepare physicians and their billing staff for the basics of modern healthcare payment models and methods of incorporating these models into addiction treatment practice. Presented by a healthcare reimbursement expert, viewers will learn the language used by health payers to improve understanding of billing and coding techniques. Some tips about determining patient coverage for services, handling prior authorization requests, and submitting claims to payers will be included.

The first in the series created to examine some of the basic and advanced issues that many may face when working with insurance companies and other health payers. The second webinar will be held on March 7th, and the third session will be a panel discussion held at the Annual Conference with ASAM members employed by health insurers.

This webinar is primarily intended for addiction medicine specialists; medical office billing staff; opioid treatment program providers; DATA-waived providers

At the conclusion of the webinar, participants should be able to:

• Recognize health care reimbursement models and common terms used by most health care payers
• Explain how health care payers make coverage decisions and discuss how that relates to their practice
• Explain recent or upcoming policy changes and identify implications or areas for provider involvement
• Assess the importance of utilization management requests, appeals, and compliance protections to make informed decisions in their practice
• Synthesize information to assist patients and staff with coverage questions and appeals
• Evaluate billing best practices to appropriately bill for tasks performed in basic or advanced situations
• Create a set of resources/list of best practices that can be used to support the participant's practice
• Analyze information about payers/reimbursement models to develop a plan for personal engagement with payer to positively impact their practice.

ACCME Accreditation Statement
The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

 AMA Credit Designation Statement:
The American Society of Addiction Medicine designates this live activity for a maximum of 1 AMA
PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Friday, November 08, 2019 | 8:00 am CT - 12:30 pm CT
Centene Corporation - Auditorium, First Floor
7700 Forsyth Boulevard
St. Louis, MO 63105

Online Portion Due: November 7, 2019

The curriculum for this course has been specifically designed for women's health providers.

Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

In the content section you will find 2 different components for the live learning. For those attending live in-person, you can skip over the live webinar portion to complete the CME Evaluation and claim your CME Certificate. 

For those attending Live-Via Webinar, you will have access to the "Live Webinar" component 30 minutes before the training. You will click on this link to access the webinar on the 29th.

Getting started: To begin the online portion of the course, please log-in to your left and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

 If you have any questions, please contact education@ASAM.org.

1. Locate the box on the right that says “View Course" and click “View Course"
   1. A new window will open with the course. Be sure your pop-up blocker is turned off.
2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
3. You will be required to pass all CME Quizzes with a grade of 70% or higher
4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center

Learning Objectives

Module 1

1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

Module 2

6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

Module 3

9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

Overall

12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

CME Information and Disclosure Listing

Date of Release: July 2015 

Approved Through: December 2019

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

ASAM CME Committee

ASAM Medical Education Council

1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
• Complete not less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD  
• If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

• 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
• Clinical Tools, Inc
• Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Qualify 

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain
• Complete no less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD
• If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Friday, September 13, 2019 | 8:30 am CT - 1:00 pm CT

Centene Corporation - Auditorium, First Floor
7700 Forsyth Boulevard
St. Louis, MO 63105

Online Portion Due: September 12, 2019

This course is offered in partnership with the American College of Obstetricians and Gynecologists. The curriculum for this course has been specifically designed for women's health providers.

Welcome to The ASAM Treatment of Opioid Use Disorder Course online access. This course covers all medications and treatments for opioid use disorder, and provides the required education needed to obtain the waiver to prescribe buprenorphine. ASAM is an approved provider by CSAT/SAMHSA of DATA 2000 training.

This is an 8-hour blended course combining 4 hours of online learning followed by 4 hours of live learning. The live portion of the course builds off content delivered in the online portion. Course faculty are expecting learners to complete the online portion before attending the live portion. You must complete both portions to receive credit for the course. 

In the content section you will find 2 different components for the live learning. For those attending live in-person, you can skip over the live webinar portion to complete the CME Evaluation and claim your CME Certificate. 

For those attending Live-Via Webinar, you will have access to the "Live Webinar" component 30 minutes before the training. You will click on this link to access the webinar on the 29th.

Getting started: To begin the online portion of the course, please log-in to your right and locate the box that says "View Course." If you do not know your password, or you have forgotten it, select "Forgot Password" and you will be emailed a link to reset your password. Detailed instructions for completing the online portion of the course can be found under the tab titled "Course Instructions."

 If you have any questions, please contact education@ASAM.org.

1. Locate the box on the right that says “View Course" and click “View Course"
   1. A new window will open with the course. Be sure your pop-up blocker is turned off.
2. Complete Module 1 and Module 2 (equivalent to four hours of instruction)
3. You will be required to pass all CME Quizzes with a grade of 70% or higher
4. Upon completion of both the two online modules and four hours of live, in-person instruction, you will be able to claim CME credit through the ASAM e-Learning Center

Learning Objectives

Module 1

1. Assess patients for the full spectrum of harmful opioid use including misuse and use disorders
2. Describe the current epidemiologic trends in opioid misuse including overdose and use disorders
3. Recall opioid use neurobiology as it applies to the development of an opioid use disorder and relapse risk
4. Summarize the laws regulating office-based opioid treatment including the Drug Addiction Treatment Act of 2000 and the Comprehensive Addiction and Recovery Act of 2016
5. Summarize the clinical pharmacology, efficacy and safety of methadone, buprenorphine and naltrexone in treating opioid use disorders

Module 2

6. Identify and assess patients who are appropriate for treatment with medications for an opioid use disorder in an office-based setting
7. Describe procedures for setting up office systems to support medication prescribing for opioid use disorders
8. Describe procedures for initiating, stabilizing, maintaining, monitoring and modifying treatment of patients on buprenorphine or naltrexone

Module 3

9. Summarize the assessment and management of patients with psychiatric and medical co-morbidities associated with opioid use disorders
10. Describe unique issues of treating adolescents, young adults, pregnant and postpartum patients maintained on medications for opioid use disorders
11. Summarize acute and chronic pain management strategies for patients with an opioid use disorder

Overall

12. Apply for a waiver to prescribe buprenorphine to patients with opioid use disorder

CME Information and Disclosure Listing

Date of Release: July 2015 

Approved Through: December 2019

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. ASAM has been awarded the highest level of Accreditation with Commendation by the ACCME as a provider of continuing medical education.

The American Society of Addiction Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

The American Society of Addiction Medicine designates this live activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 8 AMA PRA Category 1 Credit(s)™ to the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM Treatment of Opioid Use Disorder Course Program Planning Committee

ASAM CME Committee

ASAM Medical Education Council

1. Physicians, Nurse Practitioners, Clinical Nurse Specialists, and Physician Assistants who wish to obtain a waiver to prescribe buprenorphine in office-based treatment of opioid use disorder.
2. Clinicians and healthcare team members working with physicians who prescribe buprenorphine in office-based treatment of opioid use disorder.

Overview of Legislation

Physicians

The Drug Abuse Treatment Act of 2000 (DATA 2000) specifies training is necessary for physicians to obtain a waiver to engage in office‐based treatment of opioid use disorders using drugs approved by the FDA on Schedules III, IV, and V. This course addresses those requirements using a curriculum approved by CSAT/SAMHSA and ASAM, who is one of the national organizations named in the DATA 2000 legislation as eligible to prepare and administer these courses.

Nurse Practitioners & Physician Assistants

On July 22, 2016, President Obama signed the Comprehensive Addiction and Recovery Act (CARA) into law. CARA authorizes qualified NPs and PAs to become waivered to prescribe buprenorphine in office-based settings for patients with Opioid Use Disorder (OUD) for a five-year period expiring in October 2021.    

To qualify, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain  
• Complete not less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD  
• If required by state law, be supervised or work in collaboration with a qualifying physician to prescribe medications for the treatment of OUD

HHS' announcement on November 16, 2016, enables NPs and PAs to immediately begin taking the 24 hours of required training. For the full HHS announcement, click here.

NPs and PAs can begin the training immediately by taking the 8-hour buprenorphine course ASAM currently offers or that other stakeholders offer (see below for more information). The remaining 16 hours will have to be completed with one training provider. ASAM is developing multiple 16-hour training course options and formats, including collaborations with:

• 24-Hour Buprenorphine Curriculum Collaborative with the American Association of Nurse Practitioners (AANP) and the American Academy of Physician Assistants (AAPA)
• Clinical Tools, Inc
• Provider's Clinical Support System for Medication-Assisted Treatment (PCSS-MAT)

The ASAM Treatment of Opioid Use Disorder Course has been made available in part by an unrestricted educational grant from Indivior Inc.

Please ensure that your state regulations allow you to prescribe buprenorphine and other medications to treat OUD before you apply for the waiver.  Some states may have overriding state legislation that will prevent NPs and PAs from prescribing these medications even if Federal law allows it.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

Qualify 

To qualify for a waiver to treat patients with Opioid Use Disorder, NPs and PAs must: 

• Be licensed under state law to prescribe schedule III, IV, or V medications for pain
• Complete no less than 24 hours of appropriate education through a qualified provider
• Through other training or experience, demonstrate the ability to treat and manage OUD
• If required by state law, supervision or working in collaboration with a qualifying physician to prescribe medications for the treatment of OUD may be required.

Apply

• Fill out the Waiver Notification Form on SAMHSA’s website.
• Submit copies of your training certificate(s) to SAMHSA by email: infobuprenorphine@samhsa.hhs.gov or fax: 301.576.5237.

SAMHSA reviews waiver applications within 45 business days of receipt. If approved, you will receive a letter via email that confirms your waiver and includes your prescribing identification number.

Waiver applications are forwarded to the DEA. DEA regulations require your prescribing identification number to be included on all buprenorphine prescriptions for opioid dependency treatment, along with your regular DEA number.

If you have not received confirmation of receipt of your application, or if it has been more than 45 business days since submitting it, contact CSAT by email: infobuprenorphine@samhsa.hhs.gov or call 866.287.2728.

WHAT: This one-hour webinar provides an overview of the qualifications, requirements and processes related to applying for and maintaining the higher patient limit, as well as specific implications for ASAM members. Importantly, the webinar addresses practice management issues such as documenting a diversion control plan, demonstrating adherence to evidence-based guidelines, and formalizing agreements with behavioral health service providers.

WHO: Physicians interested in applying for the higher limit, as well as their practice managers and care team.

WHY: Evaluate your qualifications for the limit increase and prepare for the application and reporting processes.